Finally, validation of our findings in larger cohorts of CRC patient samples, especially in pre- and post-OXA therapy contexts, is essential to establish the clinical utility of DIRAS1 and PHB1 as predictive biomarkers. Here, PHB1 is linked to colorectal carcinoma.